CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results

Navidea Biopharma (NAVB) Misses Q4 EPS by 9c

March 23, 2022 4:04 PM EDT

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.12), $0.09 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

... More